Quantitative mass spectrometry for colorectal cancer proteomics

This review documents the uses of quantitative MS applied to colorectal cancer (CRC) proteomics for biomarker discovery and molecular pathway profiling. Investigators are adopting various labeling and label‐free MS approaches to quantitate differential protein levels in cells, tumors, and plasma/ser...

Full description

Saved in:
Bibliographic Details
Published in:Proteomics. Clinical applications 2013-01, Vol.7 (1-2), p.42-54
Main Authors: Martínez-Aguilar, Juan, Chik, Jenny, Nicholson, Judith, Semaan, Crystal, McKay, Matthew J., Molloy, Mark P.
Format: Article
Language:English
Subjects:
Animals
Biomarker
Biomarkers, Tumor - analysis
Colorectal cancer
Colorectal cancer (CRC)
Colorectal Neoplasms - diagnosis
Colorectal Neoplasms - metabolism
Colorectal Neoplasms - therapy
Humans
Mass Spectrometry
Medical research
Proteins
Proteomics
Quantitation
Rodents
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review documents the uses of quantitative MS applied to colorectal cancer (CRC) proteomics for biomarker discovery and molecular pathway profiling. Investigators are adopting various labeling and label‐free MS approaches to quantitate differential protein levels in cells, tumors, and plasma/serum. We comprehensively review recent uses of this technology to examine mouse models of CRC, CRC cell lines, their secretomes and subcellular fractions, CRC tumors, CRC patient plasma/serum, and stool samples. For biomarker discovery these approaches are uncovering proteins with potential diagnostic and prognostic utility, while in vitro cell culture experiments are characterizing proteomic and phosphoproteomic responses to disrupted signaling pathways due to mutations or to inhibition of drugable enzymes.
ISSN:1862-8346
1862-8354
DOI:10.1002/prca.201200080